Additionally, in hepatocellular carcinoma, Mel enhances the chemosensitivity of cancer cells to cisplatin by regulating the AP‐2β/hTERT and NF‐κB/COX‐2 signalling pathways [45]. Here, NFKB1 is linked to hepatocellular carcinoma.